SMi presents the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20 -21 March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance (AMR) for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of speakers
A must attend for both new and seasoned stakeholders involved in AMR and infectious disease, the industry’s premier event will provide a perfect platform for its growing "superbugs" community to network, exchange novel solutions and consolidate current strategies.
FEATURED SPEAKERS:
Sumathi Nambiar, Dir, Division of Anti-Infective Products, FDA
Richard Bax, Senior Partner, TranScrip
Lloyd Czaplewski, Dir, Chemical Biology Ventures
Chris Houchens, Branch Chief, BARDA
James Anderson, Head of Corporate Government Affairs, GSK
Aileen Rubio, Head of Biology, Spero Therapeutics
David Williams, CEO, Discuva
Martin Everett, CSO, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Dir, Pre-Clinical Services, UNT System College of Pharmacy
AGENDA HIGHLIGHTS:
EXCLUSIVE: Regulatory perspective on drug development by the Director of the FDA Antibiotics Division
Latest developments in antimicrobial peptides and chemotherapy
Comprehensive overview of government funding initiatives
Updates on clinical progress
Spotlight on animal models in drug discovery
Expanding horizons on the growing threat of anti-microbial resistance (AMR) for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of speakers
A must attend for both new and seasoned stakeholders involved in AMR and infectious disease, the industry’s premier event will provide a perfect platform for its growing "superbugs" community to network, exchange novel solutions and consolidate current strategies.
FEATURED SPEAKERS:
Sumathi Nambiar, Dir, Division of Anti-Infective Products, FDA
Richard Bax, Senior Partner, TranScrip
Lloyd Czaplewski, Dir, Chemical Biology Ventures
Chris Houchens, Branch Chief, BARDA
James Anderson, Head of Corporate Government Affairs, GSK
Aileen Rubio, Head of Biology, Spero Therapeutics
David Williams, CEO, Discuva
Martin Everett, CSO, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Dir, Pre-Clinical Services, UNT System College of Pharmacy
AGENDA HIGHLIGHTS:
EXCLUSIVE: Regulatory perspective on drug development by the Director of the FDA Antibiotics Division
Latest developments in antimicrobial peptides and chemotherapy
Comprehensive overview of government funding initiatives
Updates on clinical progress
Spotlight on animal models in drug discovery
